As share buybacks come under scrutiny, what's in store for the biopharma industry?
Stock buybacks are not to be permitted for companies that will be bailed out in the coronavirus stimulus package, Congressional leaders have signaled. To what degree the biopharma industry has relied on buybacks for earnings growth in recent years, and if the trend continues, are the big questions as scrutiny into the practice heightens and balance sheets weaken with the coronavirus pandemic wreaking havoc on global economies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.